Clinical trials: Plasma
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
This randomized phase III trial is studying total-body irradiation (TBI) and fludarabine phosphate to see how it works compared with TBI alone followed by donor stem cell transplant in treating patients with hematologic cancer.
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Aggressive Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00075478
- Testing
- Total-Body Irradiation, Fludarabine Phosphate, Mycophenolate Mofetil
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 87 people
- Sponsor
- Fred Hutchinson Cancer Center
HIV Antibodies
Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Background: The experimental product in this study, N6LS, is a human monoclonal antibody. Antibodies are one way that the human body fights infection. Monoclonal means that all the antibodies in the product are the same.
- Trial name
- VRC 609 (NCT03538626)
- Testing
- VRC-HIVMAB091-00-AB, rHuPH20
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT00560352
- Testing
- Dasatinib, Bortezomib, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
This study evaluates a new drug MGTA-145 in combination with plerixafor (Mozobil) to mobilize stem cells into the peripheral blood for collection by apheresis.
- Trial name
- NCT04552743
- Testing
- MGTA-145, Plerixafor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Surbhi Sidana, MD
Lymphoma, Multiple Myeloma
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
- Conditions
- Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00809276
- Testing
- Busulfan, Fludarabine, Cytoxan
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
This phase II trial studies the effect of selinexor when combined with carfilzomib, daratumumab, and dexamethasone in treating patients with high-risk multiple myeloma that has come back (recurrent) or has not responded to…
- Trial name
- NCT04756401
- Testing
- Carfilzomib, Daratumumab, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Academic and Community Cancer Research United
Primary Immune Thrombocytopenia
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
The study will involve patients with chronic immune thrombocytopenia. This disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons.
- Trial name
- NCT05422365
- Testing
- Intravenous immunoglobulin (IVIG), 10% solution for infusion
- Where
- 12 sites in Ukraine
- Volunteers
- 32 people
- Sponsor
- Biopharma Plasma LLC
Multiple Myeloma
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
The primary objective of this study is to: Determine the maximum tolerated dose of thalidomide used in conjunction with dose-intense melphalan, bortezomib and autologous (syngeneic) HSC support in the salvage therapy of patients…
- Trial name
- Thal/Mel/Vel (NCT01242267)
- Testing
- Thalidomide+Melphalan +Bortezomib+stem cell transplant
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Hackensack Meridian Health
Multiple Myeloma
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and…
- Trial name
- NCT01109004
- Testing
- Lenalidomide, lenalidomide, bortezomib and dexamethasone
- Where
- 54 sites in United States
- Volunteers
- 758 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Kidney Disease, Acute Kidney Injury
FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.
This is a single site study designed to evaluate the FAST mGFR Test™ in healthy adult volunteers, patients with varying degrees of chronic kidney disease (CKD), and patients with acute kidney injury (AKI).
- Trial name
- NCT01978314
- Testing
- 75 mg / 6 mL VFI™
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- FAST BioMedical
Colonic Neoplasms
PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
The purpose of this study is to compare the concentration of four different metabolites in the tumor, in adjacent mucosa and in plasma in patients with colon cancer receiving two different doses of Modufolin (arfolitixorin) and…
- Trial name
- NCT01681472
- Testing
- 6R-MTHF (arfolitixorin) 200 mg/m2, Levoleucovorin 200 mg/m2, 6R-MTHF (arfolitixorin) 60 mg/m2
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Isofol Medical AB
Myeloma-Multiple, Myeloma, Plasma-Cell
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
Background: Multiple myeloma is a blood cancer that is usually incurable. T cells are part of the immune system. Researchers think changing a person's T cells to recognize their cancer could help the person's body kill tumor…
- Trial name
- NCT03958656
- Testing
- Cyclophosphamide, Fludarabine, Rimiducid
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Hypovolemia
Gelatin in ICU and Sepsis
This prospective, double-blind randomized controlled trial evaluates the differences in terms of efficacy and safety of gelatin based resuscitation as compared to crystalloid based resuscitation in two parallel groups of patients…
- Trial name
- GENIUS (NCT02715466)
- Testing
- Balanced gelatine solution, Balanced electrolyte solution
- Where
- 12 sites in Austria, Czechia and 3 more
- Volunteers
- 167 people
- Sponsor
- B. Braun Melsungen AG
Hypertension
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)
In this study the investigators will recruit hypertensive subjects with higher than average uric acid levels to test the effect of lowering uric acid with febuxostat on several measures as listed below.
- Trial name
- NCT01328769
- Testing
- Febuxostat
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Paul N. Hopkins
Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA)
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
The purpose of this study is to determine whether plasma exchange as well as immunosuppressive therapy are effective in reducing death and end-stage renal disease (ESRD).
- Trial name
- PEXIVAS (NCT00987389)
- Testing
- Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose]
- Where
- 98 sites in United States, Australia and 13 more
- Volunteers
- 704 people
- Sponsor
- University of Pennsylvania
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory…
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00073918
- Testing
- cyclophosphamide, etoposide, iodine I 131 tositumomab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndromes, Hodgkin's Lymphoma
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Background: In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient's immune system destroys the donors' cells.
- Conditions
- Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia
- Trial name
- NCT02356159
- Testing
- Rituximab, Conditioning chemotherapy, TMS
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Factor XIII Deficiency
A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
Congenital deficiency of Factor XIII is an extremely rare hereditary disorder associated with potentially life-threatening bleeding.
- Trial name
- NCT00883090
- Testing
- FXIII Concentrate (Human)
- Where
- 6 sites in United States, Spain
- Volunteers
- 15 people
- Sponsor
- CSL Behring
Indolent Plasma Cell Myeloma, Plasma Cell Myeloma
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
This partially randomized phase I/II trial studies the side effects and best dose of anakinra when given together with lenalidomide and dexamethasone in treating patients with early stage multiple myeloma.
- Conditions
- Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT02492750
- Testing
- Anakinra, Dexamethasone, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin…
- Trial name
- NCT00750815
- Testing
- Cyclophosphamide, Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.